MiR‐182 overexpression in tumourigenesis of high‐grade serous ovarian carcinoma

@article{Liu2012MiR182OI,
  title={MiR‐182 overexpression in tumourigenesis of high‐grade serous ovarian carcinoma},
  author={Zhaojian Liu and Jinsong Liu and Miguel F. Segura and Changshun Shao and Peng Lee and Yaoqin Gong and Eva Hernando and Jian-jun Wei},
  journal={The Journal of Pathology},
  year={2012},
  volume={228}
}
Molecular pathogenesis of high‐grade serous ovarian carcinoma (HG‐SOC) is poorly understood. Recent recognition of HG‐SOC precursor lesions, defined as serous tubal intraepithelial carcinoma (STIC) in fimbria, provides a new venue for the study of early genetic changes in HG‐SOC. Using microRNA profiling analysis, we found that miR‐182 expression was significantly higher in STIC than in matched normal Fallopian tube. Further study revealed that miR‐182 was significantly overexpressed in most HG… 
miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma
TLDR
A new link between p53, miR-145 and MTDH in the regulation of tumor growth and metastasis in HGSOC is established and high level of MTDH expression correlated with poor prognosis of H GSOC.
Molecular bases of aberrant miR‐182 expression in ovarian cancer
TLDR
It is concluded that the aberrant miR‐182 expression in EOC may be due to CN gains within its coding locus, and its methylation status is associated with lower miR-182 expression.
miR-106a Represses the Rb Tumor Suppressor p130 to Regulate Cellular Proliferation and Differentiation in High-Grade Serous Ovarian Carcinoma
TLDR
The current study suggests that the RB tumor suppressor pathway is a critical regulator of growth and differentiation in HGSOC.
Cell Cycle and Senescence miR-106 a Represses the Rb Tumor Suppressor p 130 to Regulate Cellular Proliferation and Differentiation in High-Grade Serous Ovarian Carcinoma
TLDR
The current study suggests that the RB tumor suppressor pathway is a critical regulator of growth and differentiation in HGSOC, and this is the first study of miR-106a mediating proliferation and tumor differentiation inHGSOC.
OncomiR miR‐96 and miR‐182 promote cell proliferation and invasion through targeting ephrinA5 in hepatocellular carcinoma
TLDR
MiR‐96 and miR‐182 may act as oncomiRs in HCC by suppressing the expression of ephrinA5 and may play important roles in hepatocarcinogenesis.
MicroRNA‐182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas
TLDR
It is concluded that in ovarian cancer cells, miR‐182 acts as an oncogenic miRNA by directly and negatively regulating PDCD4.
Increased expression of miRNA-182 in colorectal carcinoma: an independent and tissue-specific prognostic factor.
TLDR
Investigation of the status of miR-182 expression by in situ hybridization and its underlying clinicopathologic significance for patients with CRC found that patients with high-level expression of mi R-182 had short overall survival time, suggesting a potential application in prognosis prediction and therapeutic application in CRC.
miR-182 targets CHL1 and controls tumor growth and invasion in papillary thyroid carcinoma.
miR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma.
TLDR
It is reported that miR-1236-3p expression was downregulated in HG-SOC when compared to that in normal fallopian tube tissue, and it may play an important role in the diagnosis and treatment of ovarian cancer.
miR-1236-3 p represses the cell migration and invasion abilities by targeting ZEB 1 in high-grade serous ovarian carcinoma
TLDR
It is reported that miR-1236-3p expression was downregulated in HG-SOC when compared to that in normal fallopian tube tissue, and it may play an important role in the diagnosis and treatment of ovarian cancer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Frequent Downregulation of miR-34 Family in Human Ovarian Cancers
TLDR
Part of miR-34 effects on motility and invasion may be explained by regulation of MET, which is frequently overexpressed in EOC and may be particularly important for progression to the most advanced stages.
Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor
TLDR
This work finds that miR-182, member of a miRNA cluster in a chromosomal locus frequently amplified in melanoma, is commonly up-regulated in human melanoma cell lines and tissue samples and suggests that miRNA silencing may be a worthwhile therapeutic strategy.
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
TLDR
It is concluded that mutant TP53 is a driver mutation in the pathogenesis of HGPSC cancers because it is almost invariably present in HGPSCs, and is not of substantial prognostic or predictive significance.
HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma
TLDR
The findings suggest that HMGA2 is an important molecular change significantly related to high-grade papillary serous carcinoma and is less common in other histological types of ovarian cancer.
Integrated Genomic Analyses of Ovarian Carcinoma
TLDR
It is reported that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1,BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes.
HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes.
TLDR
Findings show that HMGA2 overexpression confers a powerful oncogenic signal in ovarian cancers through the modulation of EMT genes.
Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.
TLDR
It is revealed that loss of miR-31 is associated with defects in the p53 pathway and functions in serous ovarian cancer and other cancers, suggesting that patients with cancers deficient in p53 activity might benefit from therapeutic delivery of mi R-31.
Abstract 221:TP53mutations in serous tubal intraepithelial carcinoma, the putative precursor lesion of ovarian high-grade serous carcinoma
TLDR
Findings provide cogent evidence that TP53 mutations occur in most STICs, and that both STIC and concurrent HGSC share the identical TP 53 mutations in the majority of cases.
A Genetically Defined Model for Human Ovarian Cancer
TLDR
The transformed human ovarian surface epithelial cells recapitulated many features of natural ovarian cancer including a subtype of ovarian cancer histology, formation of ascites, CA125 expression, and nuclear factor-κB-mediated cytokine activation.
HMGA2: A Potential Biomarker Complement to P53 for Detection of Early-stage High-grade Papillary Serous Carcinoma in Fallopian Tubes
TLDR
Findings of immunoreactivity for HMGA2 may lead to a novel, useful biomarker to complement p53 in the detection of early-stage serous carcinoma.
...
1
2
3
4
5
...